CoChat
Sign Up
Cited by 214Antimicrobial Peptides and ActivitiesBacterial Cancer TherapyHead and Neck Cancer Studies

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival

Open access
Kamarajan, Pachiyappan, Hayami, Takayuki, Matte, Bibiana, Liu, Yang, Danciu, Theodora, Ramamoorthy, Ayyalusamy, Worden, Francis, Kapila, Sunil, Kapila, Yvonne·2015·PLOS ONE
DOI 10.1371/journal.pone.0131008PMC PMC4489501
Open this paper in CoChat — free accountOpen PDF

Abstract

The use of small antimicrobial peptides or bacteriocins, like nisin, to treat cancer is a new approach that holds great promise. Nisin exemplifies this new approach because it has been used safely in humans for many years as a food preservative, and recent laboratory studies support its anti-tumor potential in head and neck cancer. Previously, we showed that nisin (2.5%, low content) has antitumor potential in head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo. The current studies explored a naturally occurring variant of nisin (nisin ZP; 95%, high content) for its antitumor effects in vitro and in vivo. Nisin ZP induced the greatest level of apoptosis in HNSCC cells compared to low content nisin. HNSCC cells treated with increasing concentrations of nisin ZP exhibited increasing levels of apoptosis and decreasing levels of cell proliferation, clonogenic capacity, and sphere formation. Nisin ZP induced apoptosis through a calpain-dependent pathway in HNSCC cells but not in human oral keratinocytes. Nisin ZP also induced apoptosis dose-dependently in human umbilical vein endothelial cells (HUVEC) with concomitant decreases in vascular sprout formation in vitro and reduced intratumoral microvessel density in vivo. Nisin ZP reduced tumorigenesis in vivo and long-term treatment with nisin ZP extended survival. In addition, nisin treated mice exhibited normal organ histology with no evidence of inflammation, fibrosis or necrosis. In summary, nisin ZP exhibits greater antitumor effects than low content nisin, and thus has the potential to serve as a novel therapeutic for HNSCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0131008

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Nisin ZP and nisin AP induce significant HNSCC cell apoptosis dose-dependently and beyond that in low content nisin. A and B, Graphs showing changes in percentage of apoptotic HNSCC cells (HSC-3 and UM-SCC-17B) treated with control media or media containing 2.5% nisin, 95% nisin AP, or 95% nisin ZP for 24 h. Cells were then stained using an ethidium bromide and acridine orange (EB/AO) stain and counted. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. C, Microscopic images showing morphologhy of HNSCC cells treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24 h then stained with EB/AO (Scale bars, 100 μm). D-F, Graphs showing changes in percentage of vital, apoptotic, and necrotic cells (UM-SCC-17B, HSC-3 and normal oral keratinocytes) treated with control media or media containing nisin ZP (400 or 800 μg/mL) for 24 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05 vital cells; # p<0.05 apoptotic cells.
Fig 1 Nisin ZP and nisin AP induce significant HNSCC cell apoptosis dose-dependently and beyond that in low content nisin. A and B, Graphs showing changes in percentage of apoptotic HNSCC cells (HSC-3 and UM-SCC-17B) treated with control media or media containing 2.5% nisin, 95% nisin AP, or 95% nisin ZP for 24 h. Cells were then stained using an ethidium bromide and acridine orange (EB/AO) stain and counted. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. C, Microscopic images showing morphologhy of HNSCC cells treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24 h then stained with EB/AO (Scale bars, 100 μm). D-F, Graphs showing changes in percentage of vital, apoptotic, and necrotic cells (UM-SCC-17B, HSC-3 and normal oral keratinocytes) treated with control media or media containing nisin ZP (400 or 800 μg/mL) for 24 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05 vital cells; # p<0.05 apoptotic cells.CC BY · PubMed Central
Fig 2 Nisin ZP induces calpain, caspase-8 and PARP activation in HNSCC cells dose-dependently. A, Graphs showing changes in percentage of apoptotic cells (UM-SCC-17B, HSC-3, UM-SCC-14A and OSCC-3) treated with control media or media containing nisin ZP (400 μg/mL) for 24 h. Cells were then stained with Annexin V and apoptosis was assessed by flow cytometry. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. B, Immunoblots showing calpain 1, caspase-8, caspase-3, and PARP protein levels in HNSCC (UM-SCC-17B) and C, normal human oral keratinocytes cell lysates after treatment with nisin ZP for 18 h. D, Immunoblots showing PARP and calpain 1 activation in HNSCC cell lysates after treatment for 18 h with control media, media containing nisin ZP (400 μg/mL), media containing a calpain inhibitor (ALLN, 500 nM), or media containing both a calpain inhibitor (ALLN, 500 nM) and nisin (400 μg/mL). D, An immunoblot for ß-actin shows the loading controls.
Fig 2 Nisin ZP induces calpain, caspase-8 and PARP activation in HNSCC cells dose-dependently. A, Graphs showing changes in percentage of apoptotic cells (UM-SCC-17B, HSC-3, UM-SCC-14A and OSCC-3) treated with control media or media containing nisin ZP (400 μg/mL) for 24 h. Cells were then stained with Annexin V and apoptosis was assessed by flow cytometry. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. B, Immunoblots showing calpain 1, caspase-8, caspase-3, and PARP protein levels in HNSCC (UM-SCC-17B) and C, normal human oral keratinocytes cell lysates after treatment with nisin ZP for 18 h. D, Immunoblots showing PARP and calpain 1 activation in HNSCC cell lysates after treatment for 18 h with control media, media containing nisin ZP (400 μg/mL), media containing a calpain inhibitor (ALLN, 500 nM), or media containing both a calpain inhibitor (ALLN, 500 nM) and nisin (400 μg/mL). D, An immunoblot for ß-actin shows the loading controls.CC BY · PubMed Central
Fig 3 Nisin ZP and nisin AP significantly reduce HNSCC cell proliferation time- and dose-dependently and clonogenic capacity. A. Graphs showing changes in cell proliferation in UM-SCC-17B cells treated with control media or media containing nisin AP or ZP (400 or 800 μg/mL) for 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. # Comparison between nisin AP and nisin ZP *p≤0.05. B. Graphs showing changes in cell proliferation in HNSCC cells (UM-SCC-17B, HSC-3 and UM-SCC-14A) treated with control media or media containing increasing doses of nisin ZP (100 to 800 μg/mL) for 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. ¶Comparison between the 100 μg/ml group relative to the control for UM-SCC-17B cells *pμ0.05. C. Graphs showing changes in cell proliferation in UM-SCC-17B cells treated with control media or media containing nisin ZP (400 μg/mL) for 6, 12, 24 and 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. D, The images are of UM-SCC-17B cells treated for 48h with control media or media containing nisin ZP (400 or 800 μg/mL) then cultured for 10 days, stained with crystal violet and imaged to evaluate clonogenic capacity. E, The graph shows the percentage of colonies present relative to controls for assays measuring clonogenic capacity. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. F. Graphs showing changes in cell proliferation in normal human oral keratinocytes treated with control media or media containing nisin ZP (100, 200, 400 or 800 μg/mL) for 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05.
Fig 3 Nisin ZP and nisin AP significantly reduce HNSCC cell proliferation time- and dose-dependently and clonogenic capacity. A. Graphs showing changes in cell proliferation in UM-SCC-17B cells treated with control media or media containing nisin AP or ZP (400 or 800 μg/mL) for 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. # Comparison between nisin AP and nisin ZP *p≤0.05. B. Graphs showing changes in cell proliferation in HNSCC cells (UM-SCC-17B, HSC-3 and UM-SCC-14A) treated with control media or media containing increasing doses of nisin ZP (100 to 800 μg/mL) for 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. ¶Comparison between the 100 μg/ml group relative to the control for UM-SCC-17B cells *pμ0.05. C. Graphs showing changes in cell proliferation in UM-SCC-17B cells treated with control media or media containing nisin ZP (400 μg/mL) for 6, 12, 24 and 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. D, The images are of UM-SCC-17B cells treated for 48h with control media or media containing nisin ZP (400 or 800 μg/mL) then cultured for 10 days, stained with crystal violet and imaged to evaluate clonogenic capacity. E, The graph shows the percentage of colonies present relative to controls for assays measuring clonogenic capacity. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05. F. Graphs showing changes in cell proliferation in normal human oral keratinocytes treated with control media or media containing nisin ZP (100, 200, 400 or 800 μg/mL) for 48 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05.CC BY · PubMed Central
Fig 4 Nisin ZP inhibits orasphere formation in HNSCC cells. A, Phase contrast images and B, graph showing percentage of orasphere inhibition (total area) in HNSCC cells (UM-SCC-17B) cultured under suspension conditions and treated with control media or media containing nisin ZP (100 to 800 μg/ml) for 36 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05.
Fig 4 Nisin ZP inhibits orasphere formation in HNSCC cells. A, Phase contrast images and B, graph showing percentage of orasphere inhibition (total area) in HNSCC cells (UM-SCC-17B) cultured under suspension conditions and treated with control media or media containing nisin ZP (100 to 800 μg/ml) for 36 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05.CC BY · PubMed Central
Fig 5 Nisin ZP induces endothelial cell apoptosis and inhibits angiogenic sprouting dose-dependently. A, Morphological observation of HUVEC cells treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24h. Cells were then stained with an ethidium bromide and acridine orange (EB/AO) stain, imaged, and counted (Scale bars, 100 μm). B, Graph showing percentage changes in vital, apoptotic, and necrotic HUVEC cells treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05 vital cells; # p<0.05 apoptotic cells. C, Microscopic images of sprouting assays for cells (HUVEC) treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24h then imaged and counted (Scale bars, 100 μm). D, Graphs showing the total sprout length achieved by cells treated as indicated in C. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05.
Fig 5 Nisin ZP induces endothelial cell apoptosis and inhibits angiogenic sprouting dose-dependently. A, Morphological observation of HUVEC cells treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24h. Cells were then stained with an ethidium bromide and acridine orange (EB/AO) stain, imaged, and counted (Scale bars, 100 μm). B, Graph showing percentage changes in vital, apoptotic, and necrotic HUVEC cells treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24 h. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05 vital cells; # p<0.05 apoptotic cells. C, Microscopic images of sprouting assays for cells (HUVEC) treated with control media or media containing nisin ZP (100 to 800 μg/mL) for 24h then imaged and counted (Scale bars, 100 μm). D, Graphs showing the total sprout length achieved by cells treated as indicated in C. Comparisons between groups relative to controls were analyzed by ANOVA with the level of significance set at *p<0.05.CC BY · PubMed Central
Fig 6 Nisin ZP reduces HNSCC tumor burden in mice. Images show the dissected tumors obtained from mice injected with UM-SCC-17B cells then treated with either water (control) or nisin AP or nisin ZP (400 or 800 mg/kg body weight/day) for 3 weeks.
Fig 6 Nisin ZP reduces HNSCC tumor burden in mice. Images show the dissected tumors obtained from mice injected with UM-SCC-17B cells then treated with either water (control) or nisin AP or nisin ZP (400 or 800 mg/kg body weight/day) for 3 weeks.CC BY · PubMed Central
Fig 7 Nisin ZP reduces tumor microvessel density. A, Representative images of histological sections stained with H&E (top), and histological sections immunostained for CD31 (bottom) to identify blood vessels. B, Graph showing the results of microvessel quantification from five high power fields per tumor (*p<0.05).
Fig 7 Nisin ZP reduces tumor microvessel density. A, Representative images of histological sections stained with H&E (top), and histological sections immunostained for CD31 (bottom) to identify blood vessels. B, Graph showing the results of microvessel quantification from five high power fields per tumor (*p<0.05).CC BY · PubMed Central
Fig 8 Nisin ZP does not elicit histological signs of toxicity in the liver, lung and kidney of mice. Images of H&E-stained histological sections of liver, lung and kidney from mice injected with UM-SCC-17B cells then treated with either water (control) or nisin ZP (800 mg/kg body weight/day) for 3 weeks.
Fig 8 Nisin ZP does not elicit histological signs of toxicity in the liver, lung and kidney of mice. Images of H&E-stained histological sections of liver, lung and kidney from mice injected with UM-SCC-17B cells then treated with either water (control) or nisin ZP (800 mg/kg body weight/day) for 3 weeks.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 214

Related

See all

Metadata

Authors
Kamarajan, P., Hayami, T., Matte, B., Liu, Y., Danciu, T., Ramamoorthy, A., Worden, F., Kapila, S., & Kapila, Y.
Affiliations
University of Michigan (US)
Corresponding author
Kapila, Yvonne
ORCID
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2015-07-01
Volume
10
Issue
7
Pages
e0131008
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0131008
PMC
PMC4489501
OpenAlex
W1871229721
Cited by
214
References
63
Citations by year
2026: 12 · 2025: 22 · 2024: 26 · 2023: 27 · 2022: 31 · 2021: 33 · 2020: 24 · 2019: 9 · 2018: 9 · 2017: 13 · 2016: 5 · 2015: 3
FWCI
8.42
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • University of Michigan
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Peking University
  • Ciência sem Fronteiras
  • Division of Graduate Education
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
bacteriocins, antimicrobial peptides, head and neck squamous cell carcinoma, anticancer activity, apoptosis, calpain, tumor angiogenesis, microvessel density, carcinogenesis, survival, food preservatives, oral keratinocytes, endothelial cells
MeSH terms
Animals, Carcinoma, Squamous Cell, Dose-Response Relationship, Drug, Flow Cytometry, Head and Neck Neoplasms, Humans, Mice, Nude, Mouth Neoplasms, Neoplasms, Experimental, Neovascularization, Pathologic, Nisin, Blotting, Western, Apoptosis, Cell Line, Tumor, Cell Proliferation, Mice, Microvessels, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review